Irene Kuter, DPhil, MD
Assistant Professor, Department of Medicine, Harvard Medical School
Associate Physician, Hematology/Oncology, Massachusetts General Hospital
DF/HCC Program AffiliationBreast Cancer
Over the last decade my clinical and research interests have converged on breast cancer. I have been the Principal Investigator or Site Principal Investigator in a number of clinical trials which have led to the approval of new drugs (Herceptin, Xeloda) and to the testing of promising new compounds (new antiestrogens, selective estrogen receptor modulators, novel hematopoietic growth factors and retinoids), as well as interesting compounds which may have activity in breast cancer (somatostatin analogs). I have been involved in ongoing studies of a novel breast tumor marker and have been a major investigator in a trial studying predictors of response to neoadjuvant chemotherapy. I have a particular interest in hormone therapy of breast cancer and its biological basis, and am currently the International Coordinator for a multicenter trial studying predictors of response to neoadjuvant endocrine therapy using fulvestrant.
View All Publications